Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Articles

Elevation of Factor Xla—α1-Antitrypsin Complex Levels in NIDDM Patients With Diabetic Nephropathy

  1. Takashi Murakami,
  2. Yutaka Komiyama,
  3. Hiroshi Egawa and
  4. Kenjiro Murata
  1. Department of Clinico-laboratory Medicine, Kansai Medical University Moriguchi, Osaka, Japan
  1. Address correspondence and reprint requests to Dr. Takashi Murakami, Department of Clinico-laboratory Medicine, Kansai Medical University, Fumizonocho 1, Moriguchi, Osaka 570, Japan.
Diabetes 1993 Feb; 42(2): 233-238. https://doi.org/10.2337/diab.42.2.233
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

Excess activated FXIa in plasma indicates hypercoagulability in the early contact phase. We have already developed methods for detecting the hypercoagulable state in clinical samples by our ELISA for complexed FXIa and α1AT, which has been confirmed to be the predominant inhibitor of FXIa. Indiabetes, whether the activation of FXI is associated with the development of vascular complications remains unknown, although various hemostatic abnormalities have been described. We tested the complexed FXIa-α1AT level in 45 NIDDM patients, who were divided into three groups according to the development of diabetic nephropathy, as assessed by UAE. Normoalbuminuria was defined as UAE <15 μg/min, microalbuminuria as UAE in the range of 15–200 μg/min, and albuminuria as UAE >200 μg/min. In the patients as a whole, FXIa-α1AT and TAT levels were significantly increased compared with these levels in age-matched control subjects (17.3 ± 5.7 vs. 12.4 ± 2.4 ng/ml and 2.67 ± 1.23 vs. 1.93 ± 0.45 ng/ml, respectively). No significant difference was observed between FXIa-α1AT levels in the control subjects and in the normoalbuminuric group (13.0 ± 2.1 ng/ml; n = 19). However, in the microalbuminuric (17.9 ± 3.9 ng/ml; n = 16) and albuminuric (24.1 ± 5.4 ng/ml; n = 10) groups, FXIa-α1AT levels were significantly increased compared with those in the control and normoalbuminuric group. The TAT level was not correlated with FXIa-α1AT, and no significant differences in its levels were found among these diabetic groups. We agree with the widely held belief that diabetic nephropathy is strongly related to widespread microangiopathy, and suggest that the FXIa-α1AT level reflects vascular complications that occur concomitantly with such nephropathy. Therefore, we conclude that plasma FXIa-α1AT levels may be of potential pathophysiological or clinical importance for detecting early diabetic microangiopathy.

  • Received March 26, 1992.
  • Revision received August 6, 1992.
  • Accepted August 6, 1992.
  • Copyright © 1993 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

February 1993, 42(2)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Elevation of Factor Xla—α1-Antitrypsin Complex Levels in NIDDM Patients With Diabetic Nephropathy
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Elevation of Factor Xla—α1-Antitrypsin Complex Levels in NIDDM Patients With Diabetic Nephropathy
Takashi Murakami, Yutaka Komiyama, Hiroshi Egawa, Kenjiro Murata
Diabetes Feb 1993, 42 (2) 233-238; DOI: 10.2337/diab.42.2.233

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Elevation of Factor Xla—α1-Antitrypsin Complex Levels in NIDDM Patients With Diabetic Nephropathy
Takashi Murakami, Yutaka Komiyama, Hiroshi Egawa, Kenjiro Murata
Diabetes Feb 1993, 42 (2) 233-238; DOI: 10.2337/diab.42.2.233
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas
  • In Situ Characterization of Nonmitochondrial Ca2+ Stores in Individual Pancreatic β-Cells
  • Gestational Diabetes: Antepartum Characteristics That Predict Postpartum Glucose Intolerance and Type 2 Diabetes in Latino Women
Show more Original Articles

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.